Ocular Therapeutix, Inc (OCUL) stock
OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)
Close on Nov 17, 2026Market cap $1.32BP/E –Yield –
Ocular Therapeutix gross margin
Gross margin is gross profit as a percentage of revenue.
Ocular Therapeutix's gross margin for the twelve months ending Jun 30, 2026 was 87.1%. For fiscal 2025 it was 87.3%, against 91.2% the year before. The highest annual figure on record is 91.2% in fiscal 2022.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 87.3% | −3.8 |
| FY2024 | Dec 31, 2024 | 91.2% | +0.2 |
| FY2023 | Dec 31, 2023 | 91.0% | −0.2 |
| FY2022 | Dec 31, 2022 | 91.2% | +1.3 |
| FY2021 | Dec 31, 2021 | 89.9% | +1.8 |
| FY2020 | Dec 31, 2020 | 88.0% | +43.0 |
| FY2019 | Dec 31, 2019 | 45.0% | −31.6 |
| FY2018 | Dec 31, 2018 | 76.6% | +0.4 |
| FY2017 | Dec 31, 2017 | 76.2% | −0.3 |
| FY2016 | Dec 31, 2016 | 76.5% | −5.2 |
| FY2015 | Dec 31, 2015 | 81.8% | −6.4 |
| FY2014 | Dec 31, 2014 | 88.2% | +58.2 |
| FY2012 | Dec 31, 2012 | 30.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 85.1% | −0.5 |
| Q1 FY2026 | Mar 31, 2026 | 87.7% | −0.5 |
| Q4 FY2025 | Dec 31, 2025 | 88.0% | −4.8 |
| Q3 FY2025 | Sep 30, 2025 | 87.8% | −2.1 |
| Q2 FY2025 | Jun 30, 2025 | 85.6% | −5.3 |
| Q1 FY2025 | Mar 31, 2025 | 88.2% | −2.8 |
| Q4 FY2024 | Dec 31, 2024 | 92.8% | +2.2 |
| Q3 FY2024 | Sep 30, 2024 | 89.9% | −1.0 |
| Q2 FY2024 | Jun 30, 2024 | 90.8% | −0.6 |
| Q1 FY2024 | Mar 31, 2024 | 91.0% | +0.1 |
| Q4 FY2023 | Dec 31, 2023 | 90.6% | −2.2 |
| Q3 FY2023 | Sep 30, 2023 | 90.9% | −0.2 |
| Q2 FY2023 | Jun 30, 2023 | 91.4% | +0.8 |
| Q1 FY2023 | Mar 31, 2023 | 90.9% | +0.8 |
| Q4 FY2022 | Dec 31, 2022 | 92.8% | +1.8 |
| Q3 FY2022 | Sep 30, 2022 | 91.0% | +1.8 |
| Q2 FY2022 | Jun 30, 2022 | 90.6% | −0.1 |
| Q1 FY2022 | Mar 31, 2022 | 90.1% | +2.3 |
| Q4 FY2021 | Dec 31, 2021 | 91.0% | +0.3 |
| Q3 FY2021 | Sep 30, 2021 | 89.2% | −3.1 |
| Q2 FY2021 | Jun 30, 2021 | 90.6% | −0.8 |
| Q1 FY2021 | Mar 31, 2021 | 87.9% | +19.2 |
| Q4 FY2020 | Dec 31, 2020 | 90.7% | +27.9 |
| Q3 FY2020 | Sep 30, 2020 | 92.3% | +89.6 |
| Q2 FY2020 | Jun 30, 2020 | 91.5% | +76.4 |
| Q1 FY2020 | Mar 31, 2020 | 68.6% | −5.4 |
| Q4 FY2019 | Dec 31, 2019 | 62.8% | −14.0 |
| Q3 FY2019 | Sep 30, 2019 | 2.8% | −74.1 |
| Q2 FY2019 | Jun 30, 2019 | 15.1% | −61.3 |
| Q1 FY2019 | Mar 31, 2019 | 74.0% | −2.5 |
| Q4 FY2018 | Dec 31, 2018 | 76.8% | −0.0 |
| Q3 FY2018 | Sep 30, 2018 | 76.9% | +0.8 |
| Q2 FY2018 | Jun 30, 2018 | 76.4% | +0.1 |
| Q1 FY2018 | Mar 31, 2018 | 76.5% | +0.7 |
| Q4 FY2017 | Dec 31, 2017 | 76.8% | +1.6 |
| Q3 FY2017 | Sep 30, 2017 | 76.1% | −0.4 |
| Q2 FY2017 | Jun 30, 2017 | 76.3% | – |
| Q1 FY2017 | Mar 31, 2017 | 75.8% | – |
| Q4 FY2016 | Dec 31, 2016 | 75.1% | – |
| Q3 FY2016 | Sep 30, 2016 | 76.5% | – |
See a number that looks wrong?